SHINE Medical Technologies announced last week it will receive up to $125 million of debt and equity financing in a term sheet executed with New York-based Deerfield Management Company.

According to a release, SHINE, which is working toward becoming a manufacturer of radioisotopes for nuclear medicine, will use the funds to build a new manufacturing plant in Wisconsin that will produce the isotope molybdenum-99 (moly-99).

“The momentum we’ve gained in just the past year demonstrates that SHINE is positioned to become North America’s preeminent supplier of medical isotopes,” SHINE CEO Greg Piefer said in a statement. “Deerfield’s reputation in the healthcare industry is unparalleled, and I’m thrilled they share SHINE’s vision for a reliable, domestic supply of medical isotopes.”